Summary
Global Markets Direct’s, ‘Haemophilus influenzae Type B Infections - Pipeline Review, H1 2016’, provides an overview of the Haemophilus influenzae Type B Infections pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Haemophilus influenzae Type B Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Haemophilus influenzae Type B Infections and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Haemophilus influenzae Type B Infections
- The report reviews pipeline therapeutics for Haemophilus influenzae Type B Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Haemophilus influenzae Type B Infections therapeutics and enlists all their major and minor projects
- The report assesses Haemophilus influenzae Type B Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Haemophilus influenzae Type B Infections
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Haemophilus influenzae Type B Infections
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Haemophilus influenzae Type B Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Beijing Minhai Biotechnology Co., Ltd
Biological E. Limited
Daiichi Sankyo Company, Limited
Indian Immunologicals Limited
LG Life Science LTD.
Panacea Biotec Limited
Sanofi Pasteur SA
Sinovac Biotech Ltd.
Zydus Cadila Healthcare Limited
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Haemophilus influenzae Type B Infections Overview 7
Therapeutics Development 8
Pipeline Products for Haemophilus influenzae Type B Infections - Overview 8
Pipeline Products for Haemophilus influenzae Type B Infections - Comparative Analysis 9
Haemophilus influenzae Type B Infections - Therapeutics under Development by Companies 10
Haemophilus influenzae Type B Infections - Therapeutics under Investigation by Universities/Institutes 11
Haemophilus influenzae Type B Infections - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Haemophilus influenzae Type B Infections - Products under Development by Companies 15
Haemophilus influenzae Type B Infections - Products under Investigation by Universities/Institutes 16
Haemophilus influenzae Type B Infections - Companies Involved in Therapeutics Development 17
Beijing Minhai Biotechnology Co., Ltd 17
Biological E. Limited 18
Daiichi Sankyo Company, Limited 19
Indian Immunologicals Limited 20
LG Life Science LTD. 21
Panacea Biotec Limited 22
Sanofi Pasteur SA 23
Sinovac Biotech Ltd. 24
Zydus Cadila Healthcare Limited 25
Haemophilus influenzae Type B Infections - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Combination Products 27
Assessment by Target 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
(diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis (wholl cell) + tetanus) (pentavalent) vaccine - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
(diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
(diphtheria + haemophilus influenza [serotype B] + pertussis (acellular) + tetanus) vaccine - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole-cell) + poliomyelitis + tetanus) (7-valent) vaccine - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole-cell) + tetanus) (pentavalent) vaccine - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
(diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole cell) + polio + tetanus)(pentavalent) vaccine - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
(diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole-cell) + tetanus) vaccine - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
(diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis [serotypes Mahoney + MEF-1 + Saukett] + haemophilus influenza [serotype B]) vaccine - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Eupenta - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
haemophilus influenza B vaccine - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Haemophilus influenzae B vaccine - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Haemophilus influenzae B vaccine - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
NU-300 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
VN-0105 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Haemophilus influenzae Type B Infections - Recent Pipeline Updates 52
Haemophilus influenzae Type B Infections - Dormant Projects 54
Haemophilus influenzae Type B Infections - Product Development Milestones 55
Featured News & Press Releases 55
Mar 21, 2016: BE Receives an Order from Govt. of India to Supply Liquid Pentavalent Vaccines 55
Oct 20, 2014: US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur’s Investigational Pediatric Hexavalent Vaccine 55
Apr 22, 2013: Sanofi Obtains European Approval For Six-in-One Pediatric Vaccine Hexyon/Hexacima 56
Feb 22, 2013: Sanofi Pasteur Announces EMA's CHMP Recommends Approval Of Hexyon/Hexacima Six-In-One Pediatric Vaccine 57
Oct 19, 2012: Sanofi Pasteur To Commercialize New 6-in-1 Paediatric Vaccine In European Markets 58
Appendix 59
Methodology 59
Coverage 59
Secondary Research 59
Primary Research 59
Expert Panel Validation 59
Contact Us 59
Disclaimer 60
List of Tables
Number of Products under Development for Haemophilus influenzae Type B Infections, H1 2016 8
Number of Products under Development for Haemophilus influenzae Type B Infections - Comparative Analysis, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Number of Products under Investigation by Universities/Institutes, H1 2016 11
Comparative Analysis by Late Stage Development, H1 2016 12
Comparative Analysis by Clinical Stage Development, H1 2016 13
Comparative Analysis by Early Stage Development, H1 2016 14
Products under Development by Companies, H1 2016 15
Products under Investigation by Universities/Institutes, H1 2016 16
Haemophilus influenzae Type B Infections - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2016 17
Haemophilus influenzae Type B Infections - Pipeline by Biological E. Limited, H1 2016 18
Haemophilus influenzae Type B Infections - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 19
Haemophilus influenzae Type B Infections - Pipeline by Indian Immunologicals Limited, H1 2016 20
Haemophilus influenzae Type B Infections - Pipeline by LG Life Science LTD., H1 2016 21
Haemophilus influenzae Type B Infections - Pipeline by Panacea Biotec Limited, H1 2016 22
Haemophilus influenzae Type B Infections - Pipeline by Sanofi Pasteur SA, H1 2016 23
Haemophilus influenzae Type B Infections - Pipeline by Sinovac Biotech Ltd., H1 2016 24
Haemophilus influenzae Type B Infections - Pipeline by Zydus Cadila Healthcare Limited, H1 2016 25
Assessment by Monotherapy Products, H1 2016 26
Assessment by Combination Products, H1 2016 27
Number of Products by Stage and Target, H1 2016 29
Number of Products by Stage and Route of Administration, H1 2016 31
Number of Products by Stage and Molecule Type, H1 2016 33
Haemophilus influenzae Type B Infections Therapeutics - Recent Pipeline Updates, H1 2016 52
Haemophilus influenzae Type B Infections - Dormant Projects, H1 2016 54
List of Figures
Number of Products under Development for Haemophilus influenzae Type B Infections, H1 2016 8
Number of Products under Development for Haemophilus influenzae Type B Infections - Comparative Analysis, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Comparative Analysis by Late Stage Development, H1 2016 12
Comparative Analysis by Clinical Stage Development, H1 2016 13
Comparative Analysis by Early Stage Products, H1 2016 14
Assessment by Monotherapy Products, H1 2016 26
Assessment by Combination Products, H1 2016 27
Number of Products by Targets, H1 2016 28
Number of Products by Stage and Targets, H1 2016 28
Number of Products by Routes of Administration, H1 2016 30
Number of Products by Stage and Routes of Administration, H1 2016 30
Number of Products by Molecule Types, H1 2016 32
Number of Products by Stage and Molecule Types, H1 2016 32
